Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $37

Benzinga Newsdesk www.benzinga.com Negative 61.8%

Neg 61.8% Neu 0% Pos 0%

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $83 to $37.